RKLB
Rocket Lab USA, Inc.
RKLB has the edge over TGEN overall, supported by stronger fundamentals and stronger modeled upside.
TGEN
Tecogen Inc.
TGEN has slightly lower modeled downside risk, despite its lower overall score.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
TGEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
TGEN's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
TGEN PE Valuation
TGEN has no meaningful PE right now: it lost money over the past year.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RKLB's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TGEN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB has the edge over TGEN on earnings, with more consistent year-over-year improvement.
TGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.33 | -$0.12 |
| Q2 2026 | -$0.35 | -$0.17 |
| Q1 2026 | -$0.34 | -$0.16 |
| Q4 2025 | -$0.30 | -$0.11 |
| Q3 2025 | -$0.21 | +$0.01 |
| Q2 2025 | -$0.18 | +$0.02 |
| Q1 2025 | -$0.18 | -$0.01 |
| Q4 2024 | -$0.19 | $0.00 |
TGEN lost $0.33 per share over the past year, a bigger loss than the year before.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over TGEN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
TGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.9M | +9.6% |
| Q2 2026 | $5.7M | -21% |
| Q1 2026 | $6.3M | -13% |
| Q4 2025 | $5.3M | -12% |
| Q3 2025 | $7.2M | +28% |
| Q2 2025 | $7.3M | +54% |
| Q1 2025 | $7.3M | +18% |
| Q4 2024 | $6.1M | +3% |
TGEN's revenue is down over the past year, though its latest quarter was up: $8M last quarter, up 9.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | +9.4 points |
| Q2 2026 | -37% | -18 points |
| Q1 2026 | -34% | -26 points |
| Q4 2025 | -78% | -59 points |
| Q3 2025 | -29% | -14 points |
| Q2 2025 | -19% | +12 points |
| Q1 2025 | -8.2% | +8.8 points |
| Q4 2024 | -19% | +12 points |
TGEN has the edge over RKLB on profitability, with a higher operating margin.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
TGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | +$2.2M |
| Q2 2026 | -$2.4M | +$321.5K |
| Q1 2026 | -$3.2M | -$1.8M |
| Q4 2025 | -$2.6M | -165% |
| Q3 2025 | -$3.6M | -$3.1M |
| Q2 2025 | -$2.7M | -$2.1M |
| Q1 2025 | -$1.3M | -1011% |
| Q4 2024 | $4M | +2126% |
TGEN has burned cash in most quarters: −$10M over the past year, against −$4M the year before.
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +184K shares |
| 1 year | +4.7% | +1.4M shares |
| 3 years | +21% | +5.3M shares |
| 5 years | +20% | +5M shares |
| Available history | +22% | +5.3M shares |
TGEN has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TGEN Net Leverage
TGEN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
TGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 12.3 | Oversold |
TGEN's weekly RSI is 38 (neutral) and its Stochastic is 12 (oversold).
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
TGEN PE vs Industrials Sector
| Metric | TGEN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
TGEN has no meaningful PE right now: it lost money over the past year.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB has the edge over TGEN on trend strength, trading above more of its moving averages.
TGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.28 | 2.6% below |
| 20 week MA | $3.02 | 26% below |
| 50 week MA | $3.94 | 44% below |
| 100 week MA | $4.64 | 52% below |
| 200 week MA | $2.78 | 20% below |
TGEN is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB has the edge over TGEN on returns for 2026, with the stronger performance.
TGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.26 | $1.17 | -48% |
| 2021 | $1.17 | $1.16 | -0.9% |
| 2022 | $1.16 | $1.21 | +4.3% |
| 2023 | $1.21 | $0.81 | -33% |
| 2024 | $0.81 | $1.45 | +79% |
| 2025 | $1.45 | $5.18 | +257% |
| 2026 YTD | $5.18 | $2.22 | -57% |
TGEN's yearly returns have swung widely, from +257% in 2025 to −48% in 2020. It's down 57% so far in 2026.